Stent-assisted coiling with LVIS Evo and HydroCoil embolic system: 1-year results of the SEALANT study
Open Access
- 23 July 2026
- journal article
- Published by BMJ in Journal of NeuroInterventional Surgery
Abstract
Background: More high-quality evidence for stent-assisted coiling (SAC) of cerebral aneurysms is needed. Randomized controlled trials have shown lower recurrence with the HydroCoil Embolic System (HES) compared with bare platinum coils, and self-adjudicated LVIS Evo SAC studies have demonstrated favorable safety and technical success. The objective of the SEALANT study is to investigate the safety and effectiveness of this device combination. Methods: SEALANT is an open-label, prospective, single-arm, multicenter study including patients with aneurysms up to a maximum size of 12 mm. The primary effectiveness endpoint was complete occlusion on digital subtraction angiography (DSA), and the primary safety endpoint was major ipsilateral stroke or neurological death. Adverse events and imaging were independently adjudicated. Results: 206 patients were enrolled; 193 had follow-up imaging for outcome assessment; and 164 satisfied all criteria, were treated with both study devices (including ≥90% HES), and had DSA follow-up. The participants’ mean age was 56.8±11.6 years; 65% were female. Of 212 aneurysms, 86.3% were bifurcation and 13.2% sidewall; 25.0% were previously treated and 17.9% previously ruptured; 89.6% were anterior circulation, 34.0% at the anterior communicating artery, and 30.7% at the middle cerebral artery; and 84.9% were wide-necked (neck ≥4 mm or dome/neck ratio <2). The primary effectiveness endpoint of complete occlusion was achieved in 82.1% (95% CI 76.4% to 87.9%) of aneurysms. 2.4% (95% CI 0.3% to 4.5%) of patients met the primary safety endpoint of major ipsilateral stroke or neurological death. The primary safety endpoint was significantly associated with baseline modified Rankin Scale and history of previous stroke. Conclusion: 1-year SEALANT results confirm the safety and effectiveness of SAC using LVIS Evo and HES. Trial registration number: NCT04999423 .Keywords
Funding Information
- Terumo (N/A)
This publication has 28 references indexed in Scilit:
- Frailty is a Predictor of Increased Readmissions and Increased Postoperative Complications After Elective Treatment of Unruptured AneurysmsWorld Neurosurgery, 2023
- CLinical EValuation of WEB 17 device in intracranial aneuRysms (CLEVER): procedural, 30-day and 1-year safety results for ruptured and unruptured aneurysmsJournal of NeuroInterventional Surgery, 2023
- Outcomes Associated With Intracranial Aneurysm Treatments Reported as Safe, Effective, or DurableJAMA Network Open, 2023
- Treatment of broad-based intracranial aneurysms with the LVIS EVO stent: a retrospective observational study at two centers with short- and medium-term follow-upScientific Reports, 2023
- The Hydrogel Endovascular Aneurysm Treatment Trial (HEAT): A Randomized Controlled Trial of the Second-Generation Hydrogel CoilNeurosurgery, 2020
- Risk Factors to Predict Neurologic Complications After Endovascular Treatment of Unruptured Paraclinoid AneurysmsWorld Neurosurgery, 2017
- GREAT—a randomized controlled trial comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment: procedural safety and core-lab-assessedangiographic resultsNeuroradiology, 2016
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaborationInternational Journal of Surgery, 2014
- Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trialThe Lancet, 2011
- Stents for intracranial wide-necked aneurysms: more than mechanical protectionNeuroradiology, 2008